Total Payments
$125,158
2024 Payments
$10,970
Companies
103
Transactions
1,891
Medicare Patients
41,367
Medicare Billing
$21.9M
Payment Breakdown by Category
Consulting$46,225 (36.9%)
Food & Beverage$36,590 (29.2%)
Other$34,034 (27.2%)
Travel$7,954 (6.4%)
Education$355.49 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $46,225 | 33 | 36.9% |
| Food and Beverage | $36,590 | 1,775 | 29.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,584 | 23 | 22.0% |
| Travel and Lodging | $7,954 | 40 | 6.4% |
| Honoraria | $6,450 | 6 | 5.2% |
| Education | $355.49 | 14 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14,714 | 152 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11,862 | 129 | $0 (2024) |
| Eisai Inc. | $7,989 | 52 | $0 (2024) |
| Janssen Biotech, Inc. | $7,038 | 97 | $0 (2024) |
| Celgene Corporation | $6,086 | 86 | $0 (2024) |
| Genentech USA, Inc. | $4,841 | 94 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $4,496 | 15 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $4,292 | 23 | $0 (2024) |
| Deciphera Pharmaceuticals Inc. | $3,952 | 13 | $0 (2024) |
| ABBVIE INC. | $3,716 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,970 | 228 | TAIHO ONCOLOGY, INC. ($3,040) |
| 2023 | $13,113 | 248 | Deciphera Pharmaceuticals Inc. ($3,850) |
| 2022 | $13,706 | 256 | AstraZeneca Pharmaceuticals LP ($2,431) |
| 2021 | $14,799 | 240 | Acceleron Pharma, Inc. ($2,450) |
| 2020 | $19,510 | 217 | Celgene Corporation ($3,527) |
| 2019 | $38,457 | 296 | Novartis Pharmaceuticals Corporation ($11,165) |
| 2018 | $8,079 | 221 | Spectrum Pharmaceuticals Inc. ($2,582) |
| 2017 | $6,524 | 185 | Genentech USA, Inc. ($3,626) |
All Payment Transactions
1,891 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Monoclonal Antibody | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Oncology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Oncology | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $121.15 | General |
| Category: SURGERY | ||||||
| 12/10/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $16.21 | General |
| Category: Oncology | ||||||
| 12/07/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $36.18 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Oncology | ||||||
| 11/19/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 65 | 6,101 | 427,249 | $15.9M | $4.5M |
| 2022 | 101 | 10,399 | 493,033 | $17.3M | $5.1M |
| 2021 | 92 | 11,921 | 406,152 | $16.7M | $5.2M |
| 2020 | 113 | 12,946 | 578,399 | $22.0M | $7.1M |
Total Patients
41,367
Total Services
1,904,833
Medicare Billing
$21.9M
Procedure Codes
371
All Medicare Procedures & Services
371 procedure records from CMS Medicare Utilization — Page 1 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 31 | 38,200 | $5.2M | $1.6M | 31.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 226 | 33,540 | $1.7M | $614,798 | 35.9% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 14,400 | $1.6M | $541,676 | 34.2% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 21,920 | $1.6M | $513,404 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 795 | 2,343 | $794,277 | $231,365 | 29.1% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 72 | 25,010 | $575,230 | $148,206 | 25.8% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 13 | 5,676 | $658,416 | $141,233 | 21.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 17 | 3,082 | $332,856 | $110,051 | 33.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 134 | 846 | $319,788 | $86,633 | 27.1% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 21 | 744 | $477,648 | $63,332 | 13.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 105 | 129,540 | $518,160 | $52,018 | 10.0% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 40 | 24,050 | $120,250 | $32,862 | 27.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,091 | 3,854 | $34,686 | $32,358 | 93.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 1,005 | 4,048 | $117,392 | $30,755 | 26.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 31 | 228 | $128,136 | $30,588 | 23.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 179 | 592 | $111,888 | $29,603 | 26.5% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 13 | 33,120 | $99,360 | $25,132 | 25.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 160 | 160 | $72,480 | $20,377 | 28.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 395 | 1,644 | $113,436 | $17,634 | 15.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 102 | 112 | $62,272 | $15,891 | 25.5% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 14 | 1,900 | $250,800 | $15,880 | 6.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 30 | 272 | $56,032 | $15,705 | 28.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 102 | 638 | $53,592 | $14,610 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 164 | 219 | $52,341 | $13,762 | 26.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 43 | 224 | $39,872 | $11,541 | 28.9% |
About Dr. Jay Wang, M.D
Dr. Jay Wang, M.D is a Medical Oncology healthcare provider based in Naples, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1952509606.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Wang, M.D has received a total of $125,158 in payments from pharmaceutical and medical device companies, with $10,970 received in 2024. These payments were reported across 1,891 transactions from 103 companies. The most common payment nature is "Consulting Fee" ($46,225).
As a Medicare-enrolled provider, Wang has provided services to 41,367 Medicare beneficiaries, totaling 1,904,833 services with total Medicare billing of $21.9M. Data is available for 4 years (2020–2023), covering 371 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology
- Location Naples, FL
- Active Since 07/04/2007
- Last Updated 09/02/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1952509606
Products in Payments
- Lenvima (Drug) $7,898
- CALQUENCE (Drug) $6,590
- IMBRUVICA (Drug) $6,236
- Zevalin (Drug) $6,122
- ADAKVEO (Biological) $4,976
- Tavalisse (Drug) $4,405
- QINLOCK (Drug) $3,952
- TECENTRIQ (Biological) $3,441
- VENCLEXTA (Drug) $3,432
- Copiktra (Drug) $3,281
- INQOVI (Drug) $2,969
- Tazverik (Drug) $2,880
- BRAFTOVI (Drug) $2,727
- LYNPARZA (Drug) $2,547
- Reblozyl (Drug) $2,470
- KEYTRUDA (Biological) $1,973
- SARCLISA (Biological) $1,920
- PROMACTA (Drug) $1,844
- Rubraca (Drug) $1,732
- ALUNBRIG (Drug) $1,700
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Naples
Steven Newman, Md, MD
Medical Oncology — Payments: $60,703
Medical Oncology $60,703
Dr. Andrew Lipman, M.d, M.D
Medical Oncology — Payments: $46,761
Medical Oncology $46,761
Dr. Joel Grossman, Md, MD
Medical Oncology — Payments: $24,461
Medical Oncology $24,461
Dr. Douglas Heldreth, M.d, M.D
Medical Oncology — Payments: $10,183
Medical Oncology $10,183
Dr. Susan Morgan, Md, MD
Medical Oncology — Payments: $2,023
Medical Oncology $2,023
Dr. Lillian Love, M.d, M.D
Medical Oncology — Payments: $118.48
Medical Oncology $118.48